The Filing Desk

Allogene Therapeutics

ALLO · Nasdaq · Health Care · Financials, fiscal 2018 to 2025

ALLO · Last close · November 19, 2026
$0.67
Value Allogene Therapeutics yourself

Allogene Therapeutics' revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$150 million. The diluted share count rose 13.2%.

Allogene Therapeutics, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 12, 2026 · 0001628280-26-017242 Updated
Revenue
$0M
100.0%
Net margin
—
 
Net income
−$191M
 
Free cash flow
−$150M
 
Return on equity
−53.4%
1.7 pts
Market cap
$231M
Nov 19 close
P/E
—
Loss: no P/E

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Operating margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Net margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Free cash flow margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Allogene Therapeutics does

Allogene is a clinical-stage company, which means it has no approved products yet. It is developing cancer and autoimmune treatments made from genetically engineered T cells, a type of immune cell. Its cells come from healthy donors and are meant to be used for any patient, instead of being made from each patient's own cells.

The company has three main programs: a lymphoma treatment (cema-cel) in a trial called ALPHA3, a treatment for autoimmune disease (ALLO-329), and a kidney cancer treatment (ALLO-316). It uses gene-editing technology licensed from Cellectis and Arbor Biotechnologies to reduce the risk that the donor cells attack the patient's healthy tissue.

Allogene reports no product sales. It pays for its research with money it raises, and it says it will need substantial additional financing. It was founded by executives who previously worked at Kite Pharma, a cell therapy company now owned by Gilead.

Its biggest risks, as it describes them

  • Net losses since its start, and a need for substantial new financing to keep developing its treatments.
  • Its treatments use new technology, so trial results, timing and regulatory approval are hard to predict.
  • Heavy dependence on a few lead product candidates and on partners such as Cellectis and Servier.
  • Safety events in its lymphoma trial could lead to regulatory action or product liability claims.
From Allogene Therapeutics's annual report on Form 10-K, filed March 12, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Allogene Therapeutics lost money in fiscal 2025: a net loss of $191 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments810576449373258
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage———−1,509.4x−194.7x
Current ratio9.8x9.8x12.4x8.5x7.9x
Quick ratio9.8x9.8x12.4x8.5x7.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Allogene Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Allogene Therapeutics says to expect

  • Full year 2026: operating expensesGuidance for operating expense in 2026 is expected to be approximately $165 million. GAAP Operating Expenses are expected to be approximately $225 million, including estimated non-cash stock-based compensation expense of approximately $35 million. These estimates exclude any impact from potential business development activities.
  • ALPHA3 trial: next update and enrollment timingThe Company continues to anticipate its next clinical update in mid-2027, with trial enrollment expected to be completed by year-end 2027.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Allogene Therapeutics shares on the open market, and 6 insiders sold $619,156.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 21, 2026Earl Martin DouglasSVP, General CounselSold29,697$2.12$62,958Form 4
Apr 21, 2026Annie YoshiyamaSVP, FinanceSold9,586$2.31$22,144Form 4
Mar 31, 2026Benjamin Machinas BeneskiSVP, Chief Technical OfficerSold2,867$2.50$7,168Form 4
Mar 16, 2026David D ChangPresident and CEO, DirectorSold47,763$2.47$117,975Form 4
Mar 16, 2026Benjamin Machinas BeneskiSVP, Chief Technical OfficerSold4,835$2.47$11,942Form 4
Mar 2, 2026Benjamin Machinas BeneskiSVP, Chief Technical OfficerSold7,132$2.60$18,543Form 4
Feb 2, 2026David D ChangPresident and CEO, DirectorSold95,269$1.80$171,484Form 4
Feb 2, 2026Zachary RobertsEVP of R&DSold35,700$1.77$63,189Form 4
Feb 2, 2026Geoffrey M. ParkerChief Financial OfficerSold24,001$1.76$42,242Form 4
Feb 2, 2026Earl Martin DouglasSVP, General CounselSold22,900$1.76$40,304Form 4
Feb 2, 2026Benjamin Machinas BeneskiSVP, Chief Technical OfficerSold7,549$1.73$13,060Form 4
Feb 2, 2026Annie YoshiyamaSVP, FinanceSold4,167$1.72$7,167Form 4
The latest 12 of 13 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−251,880.2%−913,685.9%—
Altman Z''−2.92−7.45−13.10
Accruals ratio−12.2%−9.6%−8.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Allogene Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Allogene TherapeuticsFY25−100.0%—————
AbbVieFY258.6%24.6%29.1%15.7%2.7x7Compare
AbCellera BiologicsFY25160.6%−289.0%−231.7%———Compare
Abeona TherapeuticsFY25—−1,536.9%−1,448.5%———Compare
AbsciFY25−38.2%−4,297.0%−3,358.3%−162.8%—3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

8 years of figures

Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue—001140000
Revenue growth————−99.9%−39.1%−76.8%−100.0%
Gross profit————————
Research and development152144193220256243192150
Operating income−193−202−258−180−336−328−273−209
Net income−212−185−316−182−340−327−258−191
Diluted EPS (US$)−7.31−1.83−2.63−1.34−2.38−2.09−1.32−0.87
Diluted shares (millions)29101120136143157195221
Cash flow
Cash from operations−45−137−115−185−220−238−200−149
Capital expenditure35166215210
Free cash flow−48−188−181−206−226−239−201−150
Dividends paid00000000
Share buybacks00000000
Acquisitions00000000
Stock-based compensation1946658184665238
Balance sheet at fiscal year end
Cash and short-term investments7215891,000810576449373258
Debt incl. finance leases————————
Total assets7747181,2281,051822643549416
Total liabilities7189148126155131126123
Shareholders' equity7036291,014925667512422292
Margins and ratios
Gross margin————————
Operating margin———−157.9%−215,087.2%−344,986.3%−1,241,813.6%—
Net margin———−159.6%−218,214.1%−344,489.5%−1,170,863.6%—
Free cash flow margin———−180.8%−144,685.9%−251,841.0%−913,609.1%—
Rule of 40 (growth + FCF margin)————−144,785.8%−251,880.2%−913,685.9%—
Return on capital————————
Return on equity—−27.7%−38.5%−18.8%−42.8%−55.5%−55.1%−53.4%
Return on assets—−24.8%−32.5%−16.0%−36.4%−44.7%−43.2%−39.6%
Net debt to EBITDA————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Allogene Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Allogene Therapeutics.